Cancer of unknown primary (CUP)

Conference Announcement

Targos together with his partner Roche is organizing an international meeting:

Cancer of unknown primary (CUP).

If you like to "Make the unknown known" join the educational meeting for oncologists and pathologists about CUP at 28th - 29th of June 2019 in Zurich.

Attendance is only possible for Oncologists and Pathologists. 


»Click here to participate

Predictive Biomarkers in Oncology

Predictive Biomarkers in Oncology

Research and experience of Targos staff - Published by Springer

20. February 2019

Targos is proud to present the new comprehensive Springer Nature publication Predictive Biomarkers in Oncology. Applications in Precision Medicine- edited by Sunil Badve, Indiana University and George Kumar, Targos Inc, co-authored by many international experts from academic, clinical, government (FDA, NCI), and industry background: demonstrating our network and expertise.

Our authors and co-authors:

George L. Kumar
Thomas Henkel
Oliver Stoss
Josef Rüschoff
Bharat Jasani
Petra Heinmöller
Gudrun Bänfer
Marius Grzelinski
Kathrina Alexander
Reinhard Büttner

We celebrate with our partner, Roche, on the success of the Phase III KATHERINE study!

Roche Logo

Press Information

Basel, 15 October 2018

We’d like to congratulate our partner Roche, on the success of their recent Phase III study investigating a new treatment option for people with HER2-positive early breast cancer with residual disease following neoadjuvant treatment. Targos is proud to have played a role in supporting the pre-screening of patients enrolled in the trial – by enabling confirmation of informative tumour characteristics such as HER2 status. We celebrate this important advance, which brings new hope to patients with this aggressive disease.

»Read more



Digital Pathology education by Targos

Philips and Targos collaborate to advance digital pathology education

Press Information
August 1, 2018

Royal Philips (NYSE: PHG, AEX: PHIA) and Targos, today announced a joint initiative to enhance digital pathology education and help drive the global standardization of clinical biomarkers. Targos is embedding Philips Pathology Education Tutor, Philips’ pathology course and assessment creation platform, into its internationally renowned biomarker and immunology training for pathologists and oncologists. Philips’ Tutor software enables Targos to transform its traditional glass microscopy courses for HER2 and PD-L1 evaluation into a digital learning experience, expanding access to high-quality digital pathology training.

»Read more

Prof. Dr. med. Reinhard Büttner

30th European Congress of Pathology: Bilbao, Spain

Prof. Dr. med. Reinhard Büttner: Chief Scientific Officer of Targos and Professor and Chairman- University of Cologne Institute for Pathology and Center for Integrated Oncology Chairs the AstraZeneca and Bristol-Myers Squibb Industry Symposium at the 30th European Congress of Pathology Meeting in Bilbao, Spain.
AstraZeneca Symposium
Developing approaches to high quality and rapid molecular testing for patient selection in cancer
Bristol-Myers Squibb Symposium
Precision medicine starts with pathology: Immuno-Oncology biomarkers and your practice

Click here for more information

PD-L1 NSCLC microscope slide

PD-L1 Testing at Targos

We offer PD-L1/PD-1 Immuno-Oncology Training and Testing.

Targos offers PD-L1 training in many indications. In addition, we also provide PD-L1 testing services within clinical trials utilizing currently commercially available PD-L1 IVD assays (SP142, SP263, 22C3, 28-8) validated in a fully CAP/CLIA compliant environment.

VENTANA PD-L1 (SP142) Assay – Solid Tumors, including NSCLC, and Urothelial Bladder Carcinoma
VENTANA PD-L1 (SP263) Assay – Solid Tumors, including NSCLC
Agilent PD-L1 IHC 22C3 pharmDx – Solid Tumors, including NSCLC
Agilent PD-L1 IHC 28-8 pharmDx – NSCLC and Melanoma. Urothelial bladder carcinoma tests will be available soon!

We also offer fully validated laboratory developed tests using anti-PD-L1 antibody clones 28-8 and E1L3N (to be available soon); and are currently working on diverse IHC multiplex assays and digital image analysis algorithms.
In addition, we also offer “off-label” application of any reagents in a “research-use” only environment as per our customer specific requirements. Please note that standard evaluation algorithms or cut-offs may not be applicable in other indications and must be technically validated prior to application.
For more information regarding PD-L1 testing or other assays, please contact us at

Prof. Dr. med. Reinhard Helmut Büttner

Prof. Dr. med. Reinhard Helmut Büttner,

Chief Scientific Officer of Targos and Professor and Chairman- University of Cologne Institute for Pathology and Center for Integrated Oncology  Chairs the Merck Sharp & Dohme (MSD) Industry Symposium “Biomarkers in Immuno-Oncology: A New Paradigm for Pathology Practice” at the 29th European Congress of Pathology Meeting in Amsterdam.

Agilent-Targos Webinar

on Basic Interpretation of PD-L1 Expression in NSCLC

Professor Bharat Jasani, Targos Molecular Pathology GmbH, Kassel, Germany

Click here for more information

Targos Educational Course

Mar. 16, 2017:

SC32-Predictive Biomarkers: Lessons from Clinical Trials
The United States and Canadian Academy of Pathology (USCAP), San Antonio, TX. March 17, 2017.

Recent developments in our molecular understanding of breast, lung and upper GI cancer and upcoming biomarkers (including PD-1/PD-L1) predicting therapy response were discussed.

Prof. Sunil Badve, MD, FRCPath, Indiana University, Indianapolis, IN, USA.
Prof. Reinhard Buettner, MD, University of Cologne and
Center for Integrated Oncology (CIO), Germany.
Prof. Josef Rüschoff, MD, Targos Molecular Pathology GmbH, Kassel, Germany.

29th European Congress of Pathology

Prof. Dr. med. Josef Rüschoff presents on HER2 gastric cancer.

Click here to view program

Updates in molecular tumor pathology

April 2-5, 2017:

Prof. Reinhard Buttner giving an interview for Qiagen’s New GeneReader Next-Generation Sequencing System

Prof. Dr. med. Reinhard Büttner

is featured in the launch of Qiagen’s New GeneReader Next-Generation Sequencing System.

Click here to watch the video

As a co-founder of "The Network Genomic Medicine (NGM) ” in Cologne, Germany, Prof. Dr. med. Reinhard Büttner  has established a centralized genomic profiling facility for malignant tumors. As a key element for personalised cancer therapy, the NGM translates large-scale molecular tumor diagnostics and individualized therapies into clinical practice.

Prof. Dr. med. Reinhard Büttner

Sept. 25-29, 2016:

Prof. Dr. med. Reinhard Büttner, Chief Scientific Officer of Targos and Scientific and Organizing Committee member of the XXXI International Congress of the International Academy of Pathology (IAP) and the 28th Congress of the European Society of Pathology (ESP) Chairs the Basic Science and Research Forum and talks about his experiences on the recent advances in molecular assessment of lung cancer. For more information about his presentation and activities, go to IAP/ESP Joint Conference, Cologne Sept 25-29, 2016 Predictive Pathology, Guiding and Monitoring Therapy.

Pathologists use the Rüschoff/Hofmann method in scoring HER2 IHC and ISH results for gastroesophageal adenocarcinoma.

Dec. 1, 2016:

Targos significantly contributed to the development of HER2 testing guidelines in gastric cancer. The current 2016 ASCO-CAP guidelines on gastric cancer was based on the original work of Prof. Josef Ruschoff and Targos. See below for publications.

    1.  Histopathology. 2008 Jun;52(7):797-805.

    2.  Lancet. 2010 Aug 28;376(9742):687-97.

For the 2016 ASCO-CAP guidelines on gastric cancer, refer to DOI: 10.1200/JCO.2016.69.4836 Journal of Clinical Oncology - published online before print November 14, 2016.

For publications of Prof. Josef Rüschoff, click the following links:

NCBI Pubmed

Google Scholar

Professor Mark Bouzyk, Professor Bharat J

Dr. Mark Bouzyk, AKESOgen (Norcross, GA), Professor Bharat Jasani (Targos Molecular Pathology GmbH, Kassel, Germany)  and Professor Reinhard Buttner (University of Cologne, Germany), at the 50th Anniversary of the foundation of Cancer research Wales Charity.  Professor Bharat Jasani is a past Trustee and Member of the Scientific Committee.

Novel route to serum based Prostate Cancer Diagnostics

Feb. 11, 2016:

Protagen AG, technology leader in the development of novel molecular diagnostic and companion diagnostic tests for autoimmune diseases and oncological indications, announced today the identification of novel protein biomarkers in prostate cancer, which are potential drug targets supporting novel strategies in precision medicine. Using the proprietary Protagen SeroTag® technology, the discovery was made in close collaboration with Professor Helmut Klocker, Medical University of Innsbruck and Oncotyrol Center for Personalized Cancer Medicine, Innsbruck, Professor Mark Rubin, Cornell University and Targos Molecular Pathology GmbH, Kassel.

»Read more

Prof. Reinhard Büttner


July 13, 2015. Cologne, Germany

Prof. Reinhard Büttner, Chief Scientific Officer of Targos participates in a landmark study that provides the first comprehensive genomic analysis of small cell lung cancer (SCLC) The study was published in Nature: July 13, 2015.

Click here for more information

Prof. Reinhard Büttner - CSO of Targos discusses how his research into lung cancer is fuelling the translation of large-scale molecular tumour diagnostics and personalised treatment strategies into clinical practice

Click here to view

Festival of Genomics

Targos to Participate in the Festival of Genomics

June 22-24, 2015. Boston, MA, USA

Click here to view

BIO International Convention

Targos to Participate in the 2015 BIO International Convention

June 16-18, 2015. Philadelphia, PA, USA

Click here to view

Dr Thomas Henkel

Mai 27, 2014. Lüneburg, Germany

Dr Thomas Henkel

CEO of Targos shares his vision for the health-care industry of tomorrow with Leuphana University of Lüneburg, Germany.

Click here to view

Forschung ist weltweit gefragt

Prof. Josef Rüschoff
Prof. Josef Rüschoff

Kasseler Firma Targos entwickelt Krebsmedikamente - Mit internationalen Preisen ausgezeichnet

Artikel bei Hessische/Niedersächsische Allgemeine (HNA) von 09.02.2012

Kassel. Vermutlich noch in diesem Monat kommt in Deutschland ein neues Medikament zur Behandlung von Hautkrebs-Patienten auf den Markt, an dessen Entwicklung die Kasseler Firma Targos einen wesentlichen Anteil hatte.

Die rund 70 Mitarbeiter des auf die Analyse von sogenannten Biomarkern spezialisierten Unternehmens sind nicht nur stolz auf diesen Erfolg: Innerhalb kurzer Zeit wurde die Kasseler Firma gleich mit zwei internationalen Preisen ausgezeichnet.

« read more »

Therapie weltweit gefragt

Fa. Targos GmbH, Germania Str. 7 in Kassel
Fa. Targos GmbH, Germania Str. 7 in Kassel

Experten für Krebsdiagnostik und -therapie arbeiten im Vorderen Westen

Artikel bei Hessische/Niedersächsische Allgemeine (HNA) von 29.12.2009

Kassel. Wenn demnächst eine weltweit neue Therapie für bestimmte Formen von Magenkrebs zugelassen wird, ist dies maßgeblich der Forschungsarbeit der Targos Molecular Pathology GmbH in Kassel zu verdanken. Das Unternehmen hat im Oktober gemeinsam mit der Pathologie Nordhessen das neu errichtete Haus der Wissenschaft in der Germaniastraße 7 bis 9 bezogen. Dies ist bereits eine international gefragte Adresse für Tumordiagnostik und Tumortherapieforschung.

Hunderte von Gewebeproben von Patienten erreichen täglich dieses Zentrum. Diese werden hier aufgearbeitet, um selbst kleinste Zellen und molekulare Bausteine beurteilen zu können. Wichtigste Aufgabe der Arbeit der Fachärzte und Wissenschaftler ist es dabei, die optimale Therapie für den Patienten herauszufinden, betont Prof. Dr. Josef Rüschoff, Senior-Partner und Medizinischer Leiter des Instituts für Pathologie Nordhessen. „Im Idealfall führt eine maßgeschneiderte Therapie zu erstaunlichen Erfolgen“, sagt der frühere Leiter der Pathologie am Klinikum Kassel.

« read more »